Azmey Matarieh, MD
Cardiovascular Disease · Elgin, ILNPI 1083718423
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $660,095 of the $762,407 with a category attached, or 86.6%. 35 manufacturers reported payments, led by Novo Nordisk at 39.6% of the total. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 981 payments — averaging $777.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$302K
- Johnson & Johnson$195K
- Boehringer Ingelheim$138K
- Lilly USA, LLC$72K
- AstraZeneca$25K
- Novartis$19K
- plus $11K from 29 others
What the payments were for
- Consulting fees$16,8602%
- Speaking & faculty fees$660,09587%
- Travel & lodging$56,9777%
- Food & beverage$28,0814%
- Education$2170%
- Entertainment$1770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 172 | $302,151 |
| Johnson & Johnson | 280 | $195,054 |
| Boehringer Ingelheim | 155 | $138,085 |
| Lilly USA, LLC | 88 | $71,599 |
| AstraZeneca | 37 | $25,116 |
| Novartis | 36 | $18,926 |
| Janssen Scientific Affairs, LLC | 1 | $2,000 |
| Abbott | 35 | $1,930 |
| Amgen | 48 | $1,854 |
| Boston Scientific | 31 | $1,287 |
| Abiomed | 20 | $866 |
| E.r. Squibb & Sons, L.L.C. | 17 | $515 |
| Edwards Lifesciences | 8 | $501 |
| Impulse Dynamics (USA) Inc. | 5 | $350 |
| Itamar Medical Inc | 2 | $345 |
| Medtronic | 3 | $255 |
| Heartflow, Inc. | 9 | $216 |
| Biotronik Inc. | 2 | $158 |
| Angiodynamics, Inc. | 1 | $142 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $129 |
| ZOLL Respicardia, Inc. | 1 | $115 |
| Shockwave Medical, Inc | 2 | $101 |
| Endotronix, Inc. | 1 | $99 |
| Esperion Therapeutics, Inc. | 2 | $92 |
| Livanova USA, Inc. | 1 | $90 |
| Pfizer | 4 | $83 |
| Cvrx, Inc. | 2 | $71 |
| Actelion Pharmaceuticals US, Inc. | 2 | $60 |
| Smith+Nephew | 1 | $53 |
| Stryker | 1 | $46 |
| Cardiva Medical, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Teleflex LLC | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$205,173
- XARELTO$193,895
- Ozempic$173,234
- FARXIGA$24,477
- RYBELSUS$20,892
- ENTRESTO$18,295
- ZEPBOUND$1,382
- Repatha$1,082
- OPTIMIZER$433
- Impella$414
- Mitra Clip system$392
- MitraClip System$377
- WatchPat$345
- WATCHMAN Access System$272
- CARDIOMEMS$251
- Watchman$220
- AngioVac$142
- MitraClip$139
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$136
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$134
How this compares
$762,407 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 341 | $360,621 |
| EliquisApixaban | 151 | $144,359 |
| JardianceEmpagliflozin | 149 | $137,275 |
| EntrestoSacubitril/Valsartan | 87 | $123,114 |
| Repatha SureclickEvolocumab | 131 | $93,847 |
| OzempicSemaglutide | 31 | $30,932 |
| Metoprolol Succinate | 550 | $9,496 |
| Nifedipine ErNifedipine | 202 | $6,185 |
| Icosapent Ethyl | 15 | $5,260 |
| Rosuvastatin Calcium | 430 | $4,969 |
| Atorvastatin Calcium | 391 | $4,097 |
| Ezetimibe | 198 | $3,677 |
| Bumetanide | 99 | $2,815 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,608 |
| Losartan Potassium | 176 | $2,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $195,054 | $360,621341 claims |
| PfizerEliquis | $83 | $144,359151 claims |
| Boehringer IngelheimJardiance | $138,085 | $137,275149 claims |
| NovartisEntresto | $18,926 | $123,11487 claims |
| Novo NordiskOzempic | $302,151 | $30,93231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Elgin
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Robert KochLibertyville$298K
- Jyothy PuthumanaChicago$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.